With the current price of $14.66, the stock of Meridian Bioscience, Inc. (NASDAQ:VIVO) concluded the trading session seeing its price drop by -1.1 points or at a loss of -6.98% compared to its previous day’s closing price of $15.76. About 1.472 million shares of the stock changed hands on the day. The trading volume of VIVO’s shares during the past session compares with the stock’s average daily trading volume of 0.734 million shares. On the other hand, a float of 42.34 million shares and a weekly performance of -14.17% make the stock worth to keep an eye on. Analysts are in agreement on an annual target price of $27.33 for VIVO’s share which suggests that the stock, price of which is currently buoying between $13.52 and $15.475, has a potential to gain 86.43%. But still, there are some analysts recommending a price below the agreed average price and one of them has given a target price of $24 to the stock.
The latest data released on August 14, 2020 shows that the short float in the Meridian Bioscience, Inc.’s stock is trending downward as short interest in VIVO shares turned down leaving more number of shares available to public for trading. Number of shares shorted in the VIVO is currently comprised of 6.19% of the float as the volume of shorted shares declined by -76672 shares. Over the past two weeks, stock’s short interests improved as number of shorted shares reduced to 2.543 million shares from the previous figure of 2.62 million shares. Stock’s average intraday volume is now standing at 957695 shares which indicate that the days to cover the shorts are nearly 2.655507.
After concluding the day’s trading, price of Meridian Bioscience, Inc. (NASDAQ:VIVO) is down -$2.42 over the week and it is -$10.29 below20-day average price. The highest price touched by the stock on the day was lower than 52-week high price of $26.58 that was attained on 08/06/20.
The stock has traded as low as $5.51 in past 52-week, and its current price is 166.06% above from that 52-week low price mark recorded on 03/13/20, which is an indicator that could increase the investors’ motivation level in taking advantage of price surge the stock has currently been going through. Stock currently has its beta at 0.92. A beta value of more than 1 represents higher volatility of a stock than that of the market and for the reason investors closely watch the behavior of such stock.
Current indicators are pointing at 25.06 as 14-days RSI of Meridian Bioscience, Inc. This means that the VIVO is currently in an overbought territory and its share’s price movement is likely to be shaky for a while. Similarly, the stochastic oscillator is indicating a momentum of 8.52%, implying stock’s share price is buoying in an overbought state.
Technical chart is showing 1st resistance point of $15.58 for the VIVO’s share while placing it at a 2nd resistance point of $16.51 to be settled at. But if the stock takes a plunge lower than the 1st support price of $13.63 then its market would become weakened. And that would likely sliding the stock price down to 2nd support price level of $12.6.
MACD oscillator is showing a reading of -1.12 for the stock which means that it is currently in the red zone. Any movement above or below the zero level of the indicator has always being noticed by the investors as it makes them compare the stock’s average measure in short-term with that in the long-term. An MACD evaluation of more than zero means that stock has a stronger short-term average than long-term average, which implies that stock’s price is likely to climb up. But an MACD below zero indicates weaker short-term average compare to the long-term average.
Piper Sandler resumed coverage of the VIVO stock on August 11, recommending Overweight rating for it while assigning the price target of $24. The stock gets a Buy recommendation from analysts at H.C. Wainwright who started covering the stock with a target price of $34 in their July 27 note to investors.William Blairanalysts upgraded their recommendation from Mkt Perform to Outperform on May 11.
The average rating of 1 for VIVO is placing the stock in bullish category at the moment. In a poll by Reuters including 4 analysts in it who kept tracking the Meridian Bioscience, Inc., 0 rated the stock as hold. Others were in different opinions for the VIVO. Out of remaining 4 analysts, 4 rated the stock as a buy or strong buy. 0 were in favor of a sell rating for the stock while advising investors to shun the stock if they already have any or otherwise not to buy it.
A quick look at other side of the picture shows that VIVO stock is ahead of earnings per share estimates with a forward price-to-earnings ratio of 14.4. Stock’s current price-to-sales (P/S) ratio of 14.4 is in front of industry’s average P/S ratio of 64.4. A comparison of Meridian Bioscience, Inc.’s trailing 12-months P/E ratio of 2.7 implies that it is trading above the industry’s average P/E ratio, which currently is 5.8.
Projection by Zacks Consensus Estimates suggests that Meridian Bioscience, Inc. (NASDAQ:VIVO) will see its current-quarter revenues drop by nearly -99.93% to be decreased to about $59.64 million. Full-year revenue of the company is however forecasted to be increased by nearly 23.95% to bring $249 million in revenues against last year revenue of $201 million. Earnings, after adjustments, are likely to surge by 15.38% to post an EPS of $0.15, while estimate for company’s full year earnings is $1.02 per share with a growth rate of 50%.